Conivaptan: a selective vasopressin antagonist for the treatment of heart failure

References

• Lloyd-Jones DM, Larson MG, Leip MS et al. Lifetime risk for developing congestive heart failure – the Framingham heart study. Circulation 106, 3068–3072 (2002).
   PubMedGoogle Scholar
• Adams KF, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209–16 (2005).
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 287, 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Gemmel I, Khand A et al. Is the prognosis of heart failure improving? Eur. J. Heart Fail. 1, 229–241 (1999).
   PubMed Web of Science ®Google Scholar
• Klein L, O’Connor CM,Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111, 2454–2460 (2005).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341, 577–585 (1999).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334, 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins M, Patterson JH et al. Vasopressin: a new target for the treatment of heart failure. Am. Heart J. 146, 9–18 (2003).
   PubMed Web of Science ®Google Scholar
• Jessup M, Brozena S. Heart Failure. N. Engl. J. Med. 348, 2007–2018 (2003).
   PubMed Web of Science ®Google Scholar
• Ishikawa SE, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin. Endocrinol. 58, 1–17 (2003).
   PubMed Web of Science ®Google Scholar
• Robertson GL, Shelton RL, Athar S et al. The osmoregulation of vasopressin. Kidney Int. 10, 25–37 (1976).
   PubMed Web of Science ®Google Scholar
• Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1-and V2-vasopressinergic receptors. Am. J. Physiol. 255, H261–H265 (1988).
   Web of Science ®Google Scholar
• Ebert TJ, Cowley AW, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J. Clin. Invest. 77, 1136–1142 (1986).
   PubMed Web of Science ®Google Scholar
• Khayyal MA, Eng C, Franzen D et al. Effects of vasopressin on the coronary circulation: reserve and regulation during ischaemia. Am. J. Physiol. 248, H516–H522 (1985).
   Google Scholar
• Reilly BA, Brostrom MA, Brostrom CO et al. Regulation of protein synthesis in ventricular myocytes by vasopressin. The role of sarcoplasmic/endoplasic reticulum Ca2+ stores. J. Biol. Chem. 273, 3747–3755 (1998).
   PubMedGoogle Scholar
• Chandrashekhar Y, Prahash AJ, Sen S et al. The role of arginine vasopressin and its receptors in the normal and failing rat heart. J. Mol. Cell. Cardiol. 35, 495–504 (2003).
   PubMed Web of Science ®Google Scholar
• Abel A, Wittau N, Wieland T et al. Cell cycle-dependent coupling of the vasopressin V1a receptor to different G-proteins. J. Biol. Chem. 275, 32543–32551 (2000).
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Auzan C, Madhun Z et al. Molecular cloning, sequencing and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem. 269, 3304–3310 (1994).
   PubMed Web of Science ®Google Scholar
• VanDerBent V, Church DJ, Vallotton MB et al. [Ca2+ ] i and protein kinase C in vasopressin-induced prostacyclin release in rat cardiomyocytes. Am. J. Physiol. 266, H597–H605 (1994).
   Google Scholar
• Nielsen S, Kwon TH, Christensen BM et al. Physiology and pathophysiology of renal aquaporins. J. Am. Soc. Nephrol. 10, 647–663 (1999).
   PubMed Web of Science ®Google Scholar
• Nielson S, Chou CL, Marples D et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc. Natl Acad. Sci. USA 92, 1013–1017 (1995).
   PubMedGoogle Scholar
• Ishikawa S, Saito T, Kasono K. Pathological role of aquaporin-2 in impaired water excretion and hyponatremia. J Neuroendocrinol 16, 293–296 (2004).
   Google Scholar
• Schrier RW, Cadnapaphornchai MA. Renal aquaporin water channels: from molecules to human disease. Prog. Biophys. Mol. Biol. 81, 117–131 (2003).
   PubMedGoogle Scholar
• Martin PY, Abraham WT, Lieming X et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J. Am. Soc. Nephrol. 10, 2165–2170 (1999).
   PubMed Web of Science ®Google Scholar
• Nielson S, Terris J, Andersen D et al. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc. Natl Acad. Sci. USA 94, 5450–5455 (1997).
   PubMedGoogle Scholar
• Xu DL, Martin PY, Ohara M et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J. Clin. Invest. 99, 1500–1505 (1997).
   PubMed Web of Science ®Google Scholar
• Szatalovitz, VL. Arnold PE, Chaimovitz C et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305, 263–266 (1981).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Francis GS, Cowley AW et al. Increased plasma arginine vasopressin in patients with congestive heart failure. J. Am. Coll. Cardiol. 1, 1385–1390 (1983).
   PubMed Web of Science ®Google Scholar
• Riegger AJG. Vasopressin and renin in high output heart failure of rats: hemodynamic effects of elevated plasma hormone levels. J. Card. Pharm. 7, 1–8 (1985).
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724–1729 (1990).
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Col. Cardiol. 24, 583–591 (1994).
   PubMed Web of Science ®Google Scholar
• Uretsky BF, Verbalis JG, Generalovich T et al. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am. J. Phys. 248, H396–H401 (1985).
   Google Scholar
• Goldsmith SR, Francis GS, Cowley AW et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. 8, 779–783 (1986).
   PubMed Web of Science ®Google Scholar
• Tahara A, Tomura Y, Wada K et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res. 38, 198–205 (1998).
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Haneda T, Osaki J et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1a receptor. Eur. J. Pharmacol. 391, 39–48 (2000).
   PubMed Web of Science ®Google Scholar
• Fukuzawa J, Haneda T, Kikucki K et al. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell Biochem. 195, 93–98 (1999).
   PubMed Web of Science ®Google Scholar
• Nicod P, Waeber B, Bussien JP et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol. 55, 1043–1047 (1985).
   PubMed Web of Science ®Google Scholar
• Nicod P, Biollaz J, Waeber B et al. Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia. Br. Heart J. 56, 433–439 (1986).
   PubMedGoogle Scholar
• Yamamura Y, Ogawa H, Chihara T et al. OPC-21268, an orally effective, non-peptide vasopressin V1 receptor antagonist. Science 252, 572–574 (1991).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 107, 2690–96 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Conner CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291, 1963–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Tahara A, Tomura Y, Wada K et al. Pharmacological profile of YM-087, a novel potent vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282, 301–308 (1997).
   PubMed Web of Science ®Google Scholar
• Burnier M, Fricker AF, Hayoz D et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur. J. Clin. Pharmacol. 55, 633–637 (1999).
   PubMed Web of Science ®Google Scholar
• Yatsu T, Tomura Y, Tahara A et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur. J. Pharmacol. 321, 225–230 (1997).
   PubMedGoogle Scholar
• Tahara A, Tomura Y, Koh-ichi W et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res. 38, 198–205 (1998).
   PubMed Web of Science ®Google Scholar
• Yatsu T. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1a and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. J. Pharmacol. 321, 225–230 (1997).
   PubMedGoogle Scholar
• Wada K, Fujimori A, Matsukawa U et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur. J. Pharmacol. 507, 145–151 (2005).
   PubMed Web of Science ®Google Scholar
• Naitoh M, Risvanis J, Balding L et al. Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition. Cardiov. Res. 54, 51–57 (2002)
   PubMedGoogle Scholar
• Burrell LM, Phillips PA, Risvanis J et al. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am. J. Physiol.. 44, H176–H182 (1998).
   Google Scholar
• Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104, 2417–23 (2001).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, Barbagelata A et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am. Heart J. 145, S51–S54 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Orlandi C, Burnett JC et al. Rationale and design of the multicenter, randomized, double-blind, placebo-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST). J. Card. Fail. 11, 260–269 (2005).
   PubMed Web of Science ®Google Scholar
• Russell SD, Selaru P, Pyne DA et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. 145, 179–186 (2003).
   PubMed Web of Science ®Google Scholar